Addressing Unmet Needs In Mrcc

Addressing Unmet Needs in mRCC

Targeted Oncology

Dr. Le on Research Needed to Address Unmet Needs in mCRC

Unmet needs in RCC

Unmet Needs in the Adjuvant Setting for Renal Cell Carcinoma

Dr Serzan on the Potential of Botensilimab/Balstilimab to Address Unmet Needs in RCC

Unmet needs in the treatment of renal cell carcinoma

Unmet needs regarding immunotherapy for renal cell carcinoma

Evolution of Targeted Therapy in mRCC

Targeted Oncology

Unmet needs for patients with advanced RCC

Rana McKay, MD, discusses the unmet needs for clinical trials addressing non-clear cell RCC

The unmet needs of kidney cancer treatment

Considerations for Using Adjuvant Therapy in mRCC

The unmet need of patients with poor-risk kidney cancer

Dr. McGregor on Unmet Needs in Advanced RCC

Dr. McKay on Unmet Needs for RCC

Key unmet needs in kidney cancer

Unmet needs for radiotherapy in RCC

Unmet Needs in RCC: ZIRCON Trial - Prof. Dr. Peter Mulders

mRCC: Resistance to VEGF and I/O

Making Decisions for Second-Line Therapy in mRCC